IRTC PRESS-RELEASE SEC Filing Analysis

Latest settled — T+20d ⚠ clustered

IRTC ▼ -9.63% at T+20d

LONG call ✗ call lost -9.63% · α vs SPY -14.91% · entry $120.80 → $109.17

Next anchor: T+60d in 6w

Last close $113.65 (close Jun 12) · -5.92% from $120.80 entry

Entry anchored
Apr 30, 03:59 PM ET
via Databento tick

T+1d

-1.34%

call -1.34% · α -1.00%

$119.18

settled 6w ago

T+5d

+3.37%

call +3.37% · α +1.02%

$124.87

settled 6w ago

T+20d

-9.63%

call -9.63% · α -14.91%

$109.17

settled 17d ago

T+60d

—

call — · α —

—

in 6w

Price Chart

Loading chart...

Executive Summary

iRhythm reported Q1 2026 revenue of $199.4M (+25.7% YoY) and GAAP EPS of -$0.43, beating consensus estimates of $194.1M and -$0.64. The company raised full-year 2026 revenue guidance to $875M-$885M and adjusted EBITDA margin to 12-13%, driven by volume growth and margin expansion across cardiology and primary care channels.

Key Financial Metrics

Guidance

$875M-$885M

raised

Free Cash Flow

-$33.1M

Gross Margin

70.9%

Actionable Insight

The strong beat and raised guidance signal accelerating volume adoption and operating leverage. Monitor upcoming 10-Q for cash flow trajectory and litigation expense trends; the stock may gap up on the guidance raise and margin inflection.

Key Facts

Q1 2026 revenue $199.4M vs consensus $194.1M (+2.7% beat)
GAAP EPS -$0.43 vs consensus -$0.64 (32.8% beat on a loss basis)
Revenue grew 25.7% YoY from $158.7M
Gross margin expanded 210 bps to 70.9%
Net loss improved to $13.9M from $30.7M YoY
Adjusted EBITDA turned positive to $14.1M from -$2.6M YoY
Raised FY2026 revenue guidance to $875M-$885M (prior undisclosed)
Raised FY2026 adjusted EBITDA margin guidance to 12-13%
Unrestricted cash and marketable securities $549.6M

Financial Impact

Revenue beat by ~$5.3M; EPS beat by $0.21 vs consensus; guidance raised by undisclosed amount

revenuegross marginnet lossadjusted EBITDAguidance

Risk Factors

Patent litigation costs ($3.7M in Q1) remain an overhang
Still GAAP-unprofitable with net loss of $13.9M
Operating cash flow negative at -$26.2M in Q1

Market Snapshot

Exchange

Nasdaq

Sector

Surgical & Medical Instruments & Apparatus

Analyst Consensus

90% bullish (21 analysts)

Documents Analyzed

This report is based on 1 press release from GlobeNewswire.

Document	Accession Number
PRESS-RELEASE Data (Synthetic)	press-3285439

13 reports for IRTC

T+1T+5T+20T+60

80% Hit rate 4 of 5 directional calls best @ T+60▲ +16.97%Feb 24, 2026

Filters

Reports for IRTC — sortable, filterable
	Type				Now
Jun 5, 2026 9d ago	8-K BULLISH ★ 5/10	$109.00 awaiting T+5	awaiting T+5	—	$113.65 (+4.27%)
May 28, 2026 17d ago	8-K NEUTRAL ★ 2/10	$115.61 $107.35	▼ −7.14%	▼ −7.46%	$113.65 (−1.70%)
May 11, 2026 4w ago	144 NEUTRAL ★ 2/10	$118.31 $110.94	▼ −6.23%	▼ −6.31%	$113.65 (−3.94%)
May 4, 2026 6w ago	Insider Cluster NEUTRAL ★ 2/10	$119.18 $116.84	▼ −1.96%	▼ −4.90%	$113.65 (−4.64%)
Apr 30, 2026 6w ago	Press Release BULLISH ★ 8/10	$120.80 $124.87	▲ +3.37%	▲ +1.02%	$113.65 (−5.92%)
Apr 27, 2026 6w ago	Press Release BULLISH ★ 7/10	$125.96 $119.18	▼ −5.38%	▼ −5.78%	$113.65 (−9.77%)
Apr 17, 2026 8w ago	DEFA14A NEUTRAL ★ 2/10	$124.91 $125.96	▲ +0.84%	▼ −0.07%	$113.65 (−9.01%)
Feb 25, 2026 15w ago	Insider Cluster BEARISH ★ 7/10	$135.90 $127.95	▲ +5.85%	▲ +4.75%	$113.65 (+16.37%)
Feb 25, 2026 15w ago	Insider Cluster BEARISH ★ 7/10	$135.90 $127.95	▲ +5.85%	▲ +4.75%	$113.65 (+16.37%)
Feb 24, 2026 15w ago	Insider Cluster BEARISH ★ 7/10	$137.10 $125.85	▲ +8.21%	▲ +7.18%	$113.65 (+17.10%)

US Market Status

Market Closed — Opens in 5h 3m

Related Tickers

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access